144481-98-1, 133242-30-5 Landiolol HCl AKSci J98964
 
 
Loading Please Wait...
  J98964    
Landiolol HCl, 95%
 



IDENTITY
CAS Number:144481-98-1, 133242-30-5
MDL Number:MFCD01937430
MF:C25H39N3O8.HCl
MW:546.05
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:122-127°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Application(s):Short-acting beta blocker

REVIEW
 Landiolol acts as a highly cardioselective, ultra-short-acting beta blocker used as an anti-arrhythmic agent. It was developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. It is approximately nine times more potent in beta-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. It has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease.

REFERENCES
[1]Iguchi, Yoichi; Wakatsuka, Hirohisa Preparation of (2,2-dimethyl-1,3-dioxolan-4S-yl)methyl 3-[4-(2S-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxyphenyl]propionate hydrochloride as beta1-adrenergic antagonist and its intermediate Jpn. Kokai Tokkyo Koho (1993), JP 05306281 A 19931119.
[2] Iguchi, Sadahiko; Iwamura, Hiroyuki; Nishizaki, Minoru; Hayashi, Akio; Senokuchi, Kazuhiko; Kobayashi, Kaoru; Sakaki, Katsuhito; Hachiya, Katsutoshi; Ichioka, Yumiko; Kawamura, Masanori Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101 Chemical & Pharmaceutical Bulletin (1992), 40(6), 1462-9.
[3] Yoshiya I.Landiolol hydrochloride, a new sympathetic beta blocker. Masui. 1998 Dec;47 Suppl:S126-32.
[4] Ogata J, Okamoto T, Minami K.Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation. Can J Anaesth. 2003 Aug-Sep;50(7):753.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of March 29, 2023


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES
 APIs and Bioactives > Beta Blockers


PubChem